Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N4O2.C4H7NO4 |
Molecular Weight | 307.3036 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC(O)=O)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=SUUWYOYAXFUOLX-ZBRNBAAYSA-N
InChI=1S/C6H14N4O2.C4H7NO4/c7-4(5(11)12)2-1-3-10-6(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
Molecular Formula | C6H14N4O2 |
Molecular Weight | 174.201 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C4H7NO4 |
Molecular Weight | 133.1027 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and as a treatment for erectile dysfunction in men. L-arginine is a nonessential amino acid that may play an important role in the treatment of heart disease due to its block arterial plaque buildup, blood clots, platelet clumping, and to increase blood flow through the coronary artery. L-arginine is commonly sold as a health supplement claiming to improve vascular health and treat erectile dysfunction in men. L-arginine, which is promoted as a human growth stimulant, has also been used in bodybuilding. In the 1800s, it was first isolated from animal horn.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628 |
44.1 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Preventing | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
310 μM |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
6219 μM |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
882 μM |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24788 M × min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
265435 M × min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
38223 M × min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
77.5 min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
41.6 min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
59.6 min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% EXPERIMENT https://www.jci.org/articles/view/103568 |
ARGININE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Disc. AE: Cardiopulmonary arrest, Metabolic acidosis... AEs leading to discontinuation/dose reduction: Cardiopulmonary arrest Sources: Page: p.621Metabolic acidosis (acute) Hyponatremia (severe) |
200 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 200 mg/kg, 3 times / day Route: oral Route: multiple Dose: 200 mg/kg, 3 times / day Sources: Page: p.63 |
unhealthy, 24 n = 11 Health Status: unhealthy Condition: Cystic fibrosis Age Group: 24 Sex: M+F Population Size: 11 Sources: Page: p.63 |
|
15 g 2 times / day multiple, oral Studied dose Dose: 15 g, 2 times / day Route: oral Route: multiple Dose: 15 g, 2 times / day Sources: Page: p.1 |
healthy, 34 ± 2.6 n = 12 Health Status: healthy Condition: Dietary supplementation Age Group: 34 ± 2.6 Sex: M+F Population Size: 12 Sources: Page: p.1 |
|
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
DLT: Gastrointestinal discomfort... Dose limiting toxicities: Gastrointestinal discomfort (20%) Sources: Page: p.200 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardiopulmonary arrest | Disc. AE | 3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Metabolic acidosis | acute Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Hyponatremia | severe Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Gastrointestinal discomfort | 20% DLT |
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
PubMed
Title | Date | PubMed |
---|---|---|
Two novel mutations (Y141H; C214Y) and previously published mutation (R142W) in the RDS-peripherin gene in autosomal dominant macular dystrophies in Spanish families. | 2001 |
|
A rare case of complete human erythrocyte AMP deaminase deficiency due to two novel missense mutations in AMPD3. | 2001 |
|
Purification and characterization of calobin II, a second type of thrombin-like enzyme from Agkistrodon caliginosus (Korean viper). | 2001 Apr |
|
Nucleocytoplasmic shuttling of heterodimeric splicing factor U2AF. | 2001 Apr 20 |
|
Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. | 2001 Feb |
|
Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. | 2001 Feb |
|
A positively charged cluster formed in the heme-distal pocket of cytochrome P450nor is essential for interaction with NADH. | 2001 Feb 16 |
|
Kinetics of CO and NO ligation with the Cys(331)-->Ala mutant of neuronal nitric-oxide synthase. | 2001 Feb 16 |
|
Increased affinity of c-Myb for CREB-binding protein (CBP) after CBP-induced acetylation. | 2001 Feb 2 |
|
Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. | 2001 Feb 23 |
|
Early glycation products produce pentosidine cross-links on native proteins. novel mechanism of pentosidine formation and propagation of glycation. | 2001 Feb 9 |
|
Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. | 2001 Jan |
|
Effect of AVT antisense oligodeoxynucleotides on AVT release induced by hypertonic stimulation in chicks. | 2001 Jan |
|
Alteration of humoral and peripheral vascular responses during graded exercise in heart failure. | 2001 Jan |
|
In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. | 2001 Jan |
|
Substitution of Asp114 or Arg116 in the fingers domain of moloney murine leukemia virus reverse transcriptase affects interactions with the template-primer resulting in decreased processivity. | 2001 Jan 12 |
|
Insights into the molecular basis for the carbenicillinase activity of PSE-4 beta-lactamase from crystallographic and kinetic studies. | 2001 Jan 16 |
|
A proposed common structure of substrates bound to mitochondrial processing peptidase. | 2001 Jan 19 |
|
Mutations that affect ligand binding to the Escherichia coli aspartate receptor: implications for transmembrane signaling. | 2001 Jan 26 |
|
Site-specific single amino acid changes to Lys or Arg in the central region of the movement protein of a hybrid bromovirus are required for adaptation to a nonhost. | 2001 Jan 5 |
|
The role of nitric oxide in bradycardia of rats with obstructive cholestasis. | 2001 Jan 5 |
|
Membrane binding motif of the P-type cardiotoxin. | 2001 Jan 5 |
|
Crystal structure and novel recognition motif of rho ADP-ribosylating C3 exoenzyme from Clostridium botulinum: structural insights for recognition specificity and catalysis. | 2001 Jan 5 |
|
A single arginyl residue in plastocyanin and in cytochrome c(6) from the cyanobacterium Anabaena sp. PCC 7119 is required for efficient reduction of photosystem I. | 2001 Jan 5 |
|
Translocation of jellyfish green fluorescent protein via the Tat system of Escherichia coli and change of its periplasmic localization in response to osmotic up-shock. | 2001 Mar 16 |
|
Identification and analysis of the acyl carrier protein (ACP) docking site on beta-ketoacyl-ACP synthase III. | 2001 Mar 16 |
|
The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. | 2001 Mar 23 |
|
Peptide leucine arginine, a potent immunomodulatory peptide isolated and structurally characterized from the skin of the Northern Leopard frog, Rana pipiens. | 2001 Mar 30 |
|
Identification of the collagen-binding site of the von Willebrand factor A3-domain. | 2001 Mar 30 |
|
The fission yeast TOR homolog, tor1+, is required for the response to starvation and other stresses via a conserved serine. | 2001 Mar 9 |
|
The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa. | 2001 Mar 9 |
|
Crystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insects. | 2001 Mar 9 |
|
The role of nitric oxide on the relaxations of rabbit corpus cavernosum induced by Androctonus australis and Buthotus judaicus scorpion venoms. | 2001 May |
|
Increased production of human proinsulin in the periplasmic space of Escherichia coli by fusion to DsbA. | 2001 Nov 30 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npc/l-arginine.html
Curator's Comment: I.V route is possible: The recommended adult dose is 30 g arginine hydrochloride (300 mL of R-Gene 10) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g arginine hydrochloride.
https://www.drugs.com/dosage/r-gene-10.html
L-arginine has been studied at oral doses of 6 to 30 g/day for a variety of conditions. Many formulations have been used.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628
A strong inward current in X. laevis oocytes expressing 5.24 (C terminus of the homologous goldfish 5.24 receptor) when L-Arg (L-arginine) was applied at 10 uM. When testing chimera h6A/5.24 (h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor) in this system, the responses were obtained with L-Arg at 100 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:08:20 GMT 2023
by
admin
on
Fri Dec 15 18:08:20 GMT 2023
|
Record UNII |
LZB1G2I725
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
3781 (Number of products:2)
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB12934MIG
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | |||
|
C024891
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | |||
|
7675-83-4
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | |||
|
11500504
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | |||
|
m2100
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID70884415
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | |||
|
LZB1G2I725
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | |||
|
100000088484
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | |||
|
231-656-8
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | |||
|
18254
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
3054-35-1
Created by
admin on Fri Dec 15 18:08:21 GMT 2023 , Edited by admin on Fri Dec 15 18:08:21 GMT 2023
|
SUPERSEDED |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |